Verastem disclosed early clinical data for VS-7375, a KRAS inhibitor designed to target the G12D mutation, and the company framed the results as supporting progression into multiple late-stage trials. In early readouts across three cancer settings—metastatic pancreatic ductal adenocarcinoma, metastatic colorectal cancer, and advanced non-small cell lung cancer—response rates were reported in a range that Verastem said met or approached expectations. The announcement came alongside a planned leadership transition and a $250 million stock offering, reflecting both financing needs and heightened competitive pressure among emerging KRAS programs. While the data are early, the company’s timing suggests an aggressive plan to establish differentiation in the next wave of KRAS-directed oncology.